{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T23:28:48Z","timestamp":1780097328951,"version":"3.54.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Chimeric antigen receptor T (CAR-T) cells targeting B-cell maturation antigen (BCMA) have been used as an effective therapy against relapsed\/refractory multiple myeloma (MM). However, the relapse rates in these patients are still high, which may be related to the poor quality of T cells after multiple chemotherapies. The case reported here demonstrated the effectiveness and safety of first-line anti-BCMA CAR-T cell therapy for high-risk MM patients, even in frailty with multiple comorbidities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A 75-year-old woman was diagnosed with biclonal gammopathy and high-risk MM with extramedullary mass in the right caput femoris. The patient was fragile with multiple comorbidities, including pneumonia, left lower limb deep venous thrombosis, and epilepsy secondary to cerebral hemorrhage. Considering the patient\u2019s fragility and comorbidities, commercial equecabtagene autoleucel, a fully human anti-BCMA CAR-T cells, as first-line CAR-T cell therapy, was proposed and accepted by the patient and her family. After one cycle of bortezomib, cyclophosphamide, and dexamethasone (VCD) regimen), she reached very good partial response (VGPR). Then her leukapheresis was performed, and the harvested cells were sent to the manufacturer for preparation. After lymphodepletion was performed using fludarabine and cyclophosphamide (FC) chemotherapy, her equecabtagene autoleucel was transfused. On day 21 after infusion, she achieved stringent complete remission (sCR) with minimal residual disease (MRD) negativity without severe toxicity. The CAR-T cells\/CD3<jats:sup>+<\/jats:sup> T cell ratio gradually increased, reaching a maximum of 54.97% on day 14, and gradually decreased, remaining at 0.03% on the 153rd day. The patient received right hip replacement plus pelvic lesion curettage 7 months after CAR-T transfusion due to pain in her right hip, but no MM cells were found in postoperative pathology. Hitherto, her deep remission persisted for 12 months without any maintenance therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>First-line anti-BCMA CAR-T cell therapy is effective and safe for high-risk MM patients, even in fragile patients with multiple comorbidities.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1564774","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T05:27:09Z","timestamp":1744781229000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["First-line anti-BCMA CAR-T cell therapy in a fragile patient with biclonal gammopathy and giant plasma cell tumor multiple myeloma with multiple comorbidities: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Yi","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beiwen","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmei","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: A review","volume":"327","author":"Cowan","year":"2022","journal-title":"Jama"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.v12.3","article-title":"Front-line treatment efficacy and clinical outcomes of elderly patients with multiple myeloma in a real-world setting: A multicenter retrospective study in China","volume":"12","author":"Bao","year":"2023","journal-title":"Cancer Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2021.08.011","article-title":"Clinical and biological characteristics and prognosis of patients with biclonal multiple myeloma","volume":"42","author":"Cheng","year":"2021","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3084-9","article-title":"Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control study","volume":"96","author":"Jurczyszyn","year":"2017","journal-title":"Ann Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.12052","article-title":"Association of frailty and high-risk immuno-nutritional score with outcomes in patients with relapsed and refractory multiple myeloma treated with chimeric antigen receptor T-cells","volume":"41","author":"Modi","year":"2023","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S196087","article-title":"Updated perspectives on the management of multiple myeloma in older patients: focus on lenalidomide","volume":"15","author":"Schoenbeck","year":"2020","journal-title":"Clin Interv Aging"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and m anagement","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J hematology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40265-017-0841-y","article-title":"Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update","volume":"78","author":"Nijhof","year":"2018","journal-title":"Drugs"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI128372","article-title":"BCMA CAR T cells: the winding path to success","volume":"129","author":"Borrello","year":"2019","journal-title":"J Clin Invest"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"B11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41375-019-0669-4","article-title":"Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better","volume":"34","author":"D'Agostino","year":"2020","journal-title":"Leukemia"},{"key":"B12","doi-asserted-by":"publisher","first-page":"S196","DOI":"10.1016\/S2152-2650(23)01908-0","article-title":"P-290 Updated long-term follow-up results of a phase 1b\/2 study (FUMANBA-1) in patients with relapsed\/refractory multiple myeloma (RRMM) treated with equecabtagene autoleucel","volume":"23","author":"Li","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.4879","article-title":"Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: the FUMANBA-1 nonrandomized clinical trial","volume":"10","author":"Li","year":"2024","journal-title":"JAMA Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"S1525-0016(24)00740-8","DOI":"10.1016\/j.ymthe.2024.11.013","article-title":"Long-term safety and efficacy of the fully human CAR-T therapy CT103A in relapsed\/refractory multiple myeloma","author":"Yu","year":"2024","journal-title":"Mol Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01488-8","article-title":"Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA","volume":"36","author":"Facon","year":"2022","journal-title":"Leukemia"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021221","article-title":"CAR T-cell therapy in multiple myeloma: mission accomplished","volume":"143","author":"Rasche","year":"2024","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00057-0","article-title":"CAR T-cell therapy for multiple myeloma: state of the art and prospects","volume":"8","author":"van de Donk","year":"2021","journal-title":"Lancet Haematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1101495","article-title":"CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"103941","DOI":"10.1016\/j.ebiom.2022.103941","article-title":"Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion","volume":"77","author":"Gumber","year":"2022","journal-title":"EBioMedicine"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21037\/sci-2020-029","article-title":"Novel progresses of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma","volume":"8","author":"Ding","year":"2021","journal-title":"Stem Cell Investig"},{"key":"B23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jtct.2023.10.022","article-title":"Chimeric antigen receptor T cell therapy for myeloma: where are we now and what is needed to move chimeric antigen receptor T cells forward to earlier lines of therapy? Expert panel opinion from the american society for transplantation and cellular therapy","volume":"30","author":"Anderson","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000600","article-title":"T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"Blood Adv"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001797","article-title":"Lingering effects of chemotherapy on mature T cells impair proliferation","volume":"4","author":"Das","year":"2020","journal-title":"Blood Adv"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jtct.2023.12.015","article-title":"Impact of frailty on outcomes after chimeric antigen receptor T cell therapy for patients with relapsed\/refractory multiple myeloma","volume":"30","author":"Davis","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.03.012","article-title":"Safety and efficacy of BCMA CAR-T cell therapy in older patients with multiple myeloma","volume":"29","author":"Reyes","year":"2023","journal-title":"Transplant Cell Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1564774\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T05:27:11Z","timestamp":1744781231000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1564774\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2025.1564774"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1564774","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"article-number":"1564774"}}